Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2016-09-30
Target enrollment:
Participant gender:
Summary
RATIONALE: Bexarotene may help cancer or abnormal cells become more like normal cells, and to
grow and spread more slowly. Colony-stimulating factors, such as GM-CSF, may increase the
number of immune cells found in bone marrow or peripheral blood. Giving bexarotene together
with GM-CSF may be an effective treatment for myelodysplastic syndrome (MDS) or acute myeloid
leukemia.
PURPOSE: This phase II trial is studying how well giving bexarotene together with GM-CSF
works in treating patients with MDS or acute myeloid leukemia.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins